Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Armata Pharmaceuticals (ARMP) Long-Term Debt Issuances (2023 - 2025)

Quarterly results put Long-Term Debt Issuances at $15.0 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $25.0 million (down 28.34% YoY), and the annual figure for FY2025 was $25.0 million, down 28.34%.

Armata Pharmaceuticals has reported Long-Term Debt Issuances over the past 4 years, most recently at $15.0 million for Q3 2025.

  • Long-Term Debt Issuances reached $15.0 million in Q3 2025 per ARMP's latest filing, up from $10.0 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $34.9 million in Q1 2024 and bottomed at -$4.3 million in Q3 2023.
  • Median Long-Term Debt Issuances over the past 3 years was $12.5 million (2025), compared with a mean of $14.1 million.
  • The largest annual shift saw Long-Term Debt Issuances rose 17.89% in 2024 before it tumbled 71.34% in 2025.
  • Over 3 years, Long-Term Debt Issuances stood at -$4.3 million in 2023, then soared by 911.18% to $34.9 million in 2024, then crashed by 57.01% to $15.0 million in 2025.
  • Business Quant data shows Long-Term Debt Issuances for ARMP at $15.0 million in Q3 2025, $10.0 million in Q1 2025, and $34.9 million in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 2.73 Mn
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn -
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn -
10 Armata Pharmaceuticals 301.92 Mn 297.17 Mn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2025 15.00 Mn
Sep 30, 2025 15.00 Mn
Mar 31, 2025 10.00 Mn
Mar 31, 2025 10.00 Mn
Mar 31, 2024 34.89 Mn
Mar 31, 2024 34.89 Mn
Sep 30, 2023 -4.30 Mn
Sep 30, 2023 -4.30 Mn
Jun 30, 2023 -368,000.00
Jun 30, 2023 -368,000.00
Mar 31, 2023 29.59 Mn
Mar 31, 2023 29.59 Mn